Clinical Trials

Other hematologic neoplasmPlasma cell

61 enrolled

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT07116616 2026-04-03

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

166 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT07510100 2026-04-03

FUMANBA-04

17 enrolled

Multiple Myeloma, Recurrence

NCT05927571 2026-04-02

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

120 enrolled

Multiple Myeloma, Recurrence

NCT03761108 2026-04-01

LINKER-MM1

387 enrolled 3 FDA

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05552976 2026-04-01

SUCCESSOR-2

606 enrolled

Multiple Myeloma, Recurrence

NCT06215118 2026-03-27

MagnetisMM-30

87 enrolled

Multiple Myeloma, Recurrence

NCT04756726 2026-03-25

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

224 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05519085 2026-03-24

SUCCESSOR-1

Phase 3 Recruiting

810 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02952508 2026-03-18

CLOVER-WaM

120 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT06068400 2026-03-17

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase NA Terminated

1 enrolled

Multiple Myeloma, Recurrence

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1/2 Completed

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

130 enrolled

Multiple Myeloma, Recurrence

NCT07280013 2026-03-05

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

60 enrolled

Bites and Stings, Multiple Myeloma, Recurrence

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

312 enrolled

Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

228 enrolled

Multiple Myeloma, Recurrence

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

MyeloidOther hematologic neoplasmPlasma cell

21 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05014412 2026-02-10

MagnetisMM-9

Phase 2 Completed

86 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT06297226 2026-02-10

QUINTESSENTIAL

Phase 2 Recruiting

230 enrolled

Multiple Myeloma, Recurrence

NCT03374085 2026-02-09

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 1/2 Terminated

200 enrolled

Multiple Myeloma, Recurrence

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

70 enrolled

Multiple Myeloma, Recurrence

NCT07369895 2026-01-27

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

18 enrolled

Multiple Myeloma, Recurrence

NCT05714839 2026-01-23

DREAMM-20

153 enrolled

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

90 enrolled

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

300 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence

NCT04824794 2025-12-22

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Phase 1/2 Terminated

130 enrolled

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT05503550 2025-12-16

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

No longer available

Multiple Myeloma, Recurrence

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Approved for marketing

Multiple Myeloma, Recurrence

NCT04398680 2025-12-04

DREAMM 13

Phase 1 Withdrawn

Multiple Myeloma, Recurrence

NCT06304636 2025-11-24

DC15-MM-01

Phase 1 Terminated

4 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05164250 2025-11-10

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Approved for marketing

Multiple Myeloma, Recurrence

NCT03837509 2025-11-04

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

15 enrolled 15 charts

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05064358 2025-10-07

DREAMM 14

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT06479954 2025-10-02

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Active not recruiting

1 enrolled

Multiple Myeloma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

160 enrolled

Multiple Myeloma, Recurrence

NCT06292780 2025-09-18

LINKER-AL2

220 enrolled

Multiple Myeloma, Recurrence

NCT06381141 2025-09-18

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

30 enrolled